# ORIGIN ENDOSCOPY INC.: Development of EpiMAX, a first-in-class injectable hemostatic agent for long-acting hemostasis of gastrointestinal bleeding

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | ORIGIN ENDOSCOPY INC. |
| Location | BALTIMORE, MD |
| Project | Development of EpiMAX, a first-in-class injectable hemostatic agent for long-acting hemostasis of gastrointestinal bleeding |
| Project number | 1R44DK145328-01A1 |
| Mechanism | R44 |
| Institute | National Institute of Diabetes and Digestive and Kidney Diseases |
| Award | $1,212,289 |
| Awarded | 2026-09-14 |
| Project period | 2026-09-15 to 2028-08-31 |
| UEI | FNG7WGQLJ2U6 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11407431). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.